hotspot -WSS

hotspot

author：Wikipedia 2025-09-06 01:23:31 - browse：74

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： ASCO: AstraZeneca says CAR

WSS

What don’t we know about an Alzheimer’s drug side effect?

Rep. Raul Ruiz on the physician shortage and more

Flagship Pioneering launches a new biotech in two countries

Shifting the focus from loneliness to social health

Let's speed up science by embracing open access publishing

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Drug repurposing or repositioning? The language matters

Flagship Pioneering launches a new biotech in two countries

Peter Hotez and the public health issue of online harassment

What don’t we know about an Alzheimer’s drug side effect?

Apple is now the first public company to be valued at $3 trillion

Will the market for weight loss drugs really reach $100 billion?

In Memoriam: Notable people who died in 2023

The Pandemic Treaty must support building strong health systems

Cancer drug shortages should be causing more outrage

With clinical trial data readouts, here's how to spot spin

focus

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO: Palliative care found as helpful given virtually as in person

Diagnostic tests are hitting their mathematical limits

Diagnostic tests are hitting their mathematical limits

ASCO: Palliative care found as helpful given virtually as in person

How to increase colonoscopy rates? Looks like an AI can help

focus

leisure time

Wikipedia

Wikipedia